Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - Possible role in bone homeostasis

European Journal of Endocrinology

Volumn 145, Issue 6, 2001, Pages 685-690

  Ueland, T ^a   Bollerslev, J ^a   Godang, K ^a   Muller F ^a   Froland S S ^a   Aukrust, P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; GLUCOCORTICOID; HYDROCORTISONE; OSTEOCALCIN; OSTEOPROTEGERIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ACROMEGALY; ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BONE METABOLISM; BONE REMODELING; CARBOXY TERMINAL SEQUENCE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CORRELATION FUNCTION; CUSHING SYNDROME; FEMALE; GENDER; GROWTH HORMONE DEFICIENCY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; OSTEOCLAST; PARAMETER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY;

EID: 0035210701     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1450685     Document Type: Article

References (31)

1. Interleukins in the control of osteoclast differentiation
2. Control of osteoclast differentiation
3. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity
4. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
5. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
6. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
7. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
8. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
9. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy
10. Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency
11. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection - Correlations to clinical, immunologic, and virologic parameters
12. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency - Possible immunologic and clinical consequences
13. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
14. Primary immunodeficiency diseases
15. Cellular abnormalities in common variable immunodeficiency
16. Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes
17. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
18. Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome
19. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
20. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
21. Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immuno-deficiency virus infection: Modulation of IL-10 and 1g production after intravenous Ig infusion
22. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
23. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
24. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
25. Glucocorticoid decreases circulating osteoprotegerin (OPG): Possible mechanism for glucocorticoid induced osteoporosis
26. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
27. Iliac crest bone mass and remodelling in acromegaly
28. Bone mineral density and parameters of bone metabolism in patients with acromegaly
29. Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism
30. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
31. The effect of a single dose of osteoprotegerin in postmenopausal women